4.4 Article

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study

Uwe Reuter et al.

Summary: Lasmiditan showed superior efficacy compared to placebo in triptan insufficient responders, with benefits in pain relief, pain freedom, migraine-related disability freedom, and most bothersome symptom freedom. The consistency of effects across attacks was also observed, independent of prior response to triptans.

CEPHALALGIA (2022)

Article Clinical Neurology

Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study

Astrid Gendolla et al.

Summary: A retrospective study of migraine patients in Germany revealed a considerable proportion of patients with triptan contraindications or who discontinued triptan use. The study provided insights into medication use, attitudes, and behaviors regarding triptans among these patients.

NEUROLOGY AND THERAPY (2022)

Article Clinical Neurology

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis

Andrew M. Blumenfeld et al.

Summary: The study found that ubrogepant had similar efficacy and tolerability for the acute treatment of migraine in participants classified as triptan responders, triptan-insufficient responders, and triptan-naive based on their historical experience with triptans. There was no significant impact of historical triptan experience on ubrogepant efficacy, and adverse event incidence did not differ significantly across historical triptan experience subgroups.

HEADACHE (2021)

Article Clinical Neurology

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani et al.

Summary: This update aims to incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. It provides practical recommendations based on expanded evidence base and emerging expert consensus, in the absence of a formal guideline.

HEADACHE (2021)

Article Clinical Neurology

Acute treatment patterns in patients with migraine newly initiating a triptan

Richard B. Lipton et al.

CEPHALALGIA (2020)

Article Medicine, General & Internal

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Clinical Neurology

Triptan persistency among newly initiated users in a pharmacy claims database

Bozena J. Katic et al.

CEPHALALGIA (2011)

Article Medicine, General & Internal

Switching patients with migraine from sumatriptan to other triptans increases primary care costs

N Savani et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)

Article Clinical Neurology

Placebo response in clinical randomized trials of analgesics in migraine

L Bendtsen et al.

CEPHALALGIA (2003)

Article Clinical Neurology

What do patients with migraine want from acute migraine treatment?

RB Lipton et al.

HEADACHE (2002)